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Abstract
There are currently no standardized diagnostic tests available for the reliable detection of AmpC b-lactamases in Klebsiella spp., Escheri-
chia coli, Proteus mirabilis and Salmonella spp. A study was designed to evaluate a conﬁrmation disk test using cefotetan (CTT) and cefoxi-
tin (FOX) with phenylboronic acid (PBA). It also investigated the most suitable screening concentrations of FOX, ceftriaxone (CRO)
and ceftazidime (CAZ) for the detection of AmpC b-lactamases. A total of 126 control (consisting of 11 laboratory and 115 well-
characterized clinical strains) and 29 840 non-repeat clinical isolates were included. FOX with PBA used in a conﬁrmation test and
CRO and CAZ as screening agents were found to be unreliable. FOX at ‡ 32 mg/L was the best screening agent and CTT with PBA
was the best conﬁrmation test. Of the clinical isolates 635 (2%) were found to be resistant to cefoxitin (MIC ‡ 32 ug/mL) and 332
(52%) were AmpC positive. E. coli was the most common organism with AmpC b-lactamases and was mostly present in urines from
community patients. It is recommended that laboratories use FOX at 32 mg/L as a screening agent and perform a disk test with CTT
and PBA to conﬁrm the presence of an AmpC cephalosporinase in isolates of Klebsiella spp., E. coli, Salmonella spp. and P. mirabilis. This
approach is convenient, practical and easy to incorporate into the workﬂow of a clinical laboratory. False-positive AmpC detection may
occur with KPC-producing bacteria when inhibitor-based methods are used.
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Introduction
Enterobacteriaceae with inducible cephalosporinases, such as
Enterobacter cloacae, Citrobacter freundii, Serratia marcescens,
Morganella morganii and Providencia stuartii, may become resis-
tant to oxyimino- (e.g. cefotaxime, ceftazidime) and 7-a-
methoxy (i.e. cephamycins) cephalosporins and monobactams
by overproducing their chromosomal AmpC b-lactamases
[1]. In Klebsiella pneumoniae, Salmonella spp. and Proteus mira-
bilis, which lack chromosomal b-lactamases, this type of resis-
tance can be mediated by plasmid-encoded AmpC
cephalosporinases [2]. Escherichia coli possesses genes encod-
ing chromosomal non-inducible AmpC b-lactamases that are
regulated by weak promoters and strong attenuators, result-
ing in low amounts of the cephalosporinase [3]. Surveys of
resistance mechanisms in cephamycin-resistant E. coli have
identiﬁed a promoter or attenuator mutation, which results
in the upregulation of naturally occurring chromosomal
AmpC b-lactamase production [4]. Occasionally, cephamy-
cin-resistant E. coli can also produce plasmid-mediated AmpC
b-lactamases [2].
Plasmid-mediated AmpC cephalosporinases are derivatives
of the chromosomally encoded AmpC b-lactamases of bacte-
ria such as Enterobacter, C. feundii, M. morganii, Aeromonas
spp. and Hafnia alvei [2]. These enzymes are not inhibited by
commercial b-lactamase inhibitors, such as clavulanic acid,
sulbactam and tazobactam, although different types of inhibi-
tors, such as boronic acid and cloxacillin, have shown good
inhibition. The genes are also typically encoded on large plas-
mids containing additional antibiotic resistance genes, which
leaves few therapeutic options.
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A recent study from the Calgary Health Region has identi-
ﬁed AmpC-producing E. coli as an emerging pathogen in the
community that commonly causes urinary tract infections in
older women [5]. A cost-effective, practical diagnostic
approach was needed to establish accurate detection of
organisms producing AmpC cephalosporinases. There are no
guidelines from the CLSI available for the detection of bacte-
ria with AmpC b-lactamases and the best approach to date
is to screen for resistance to a cephamycin (e.g. cefoxitin)
and/or oxyimino- (e.g. cefotaxime, ceftazidime) cephalospo-
rins in isolates such as Klebsiella spp., E. coli, P. mirabilis and
Salmonella spp. Such resistance, in combination with a nega-
tive CLSI extended-spectrum b-lactamase conﬁrmatory test,
is a possible, but non-speciﬁc, indicator for AmpC produc-
tion [6]. The use of an AmpC inhibitor, boronic acid, has
recently been described as an effective conﬁrmation test for
the detection of organisms with AmpC b-lactamases [7,8].
This method has not been extensively veriﬁed or validated
for routine use in clinical laboratories.
This study reports on the incorporation of a boronic acid
disk conﬁrmation test in the clinical laboratory. It describes
the most appropriate screening criteria for the detection of
AmpC cephalosporinases in Klebsiella spp., E. coli, P. mirabilis
and Salmonella spp. It also investigates the prevalence
of these enzymes among recent clinical isolates from the
Calgary Health Region during 2006–2007.
Materials and methods
Overview of study
The ﬁrst part of the study was designed to verify the boro-
nic acid disk conﬁrmation test using control strains and
recent clinical isolates from previous studies as positive and
negative controls [5,9] (Table 1). Cefotetan (CTT) and
cefoxitin (FOX) with and without phenylboronic acid (PBA)
as substrates for AmpC were initially included in the disk
test. The second part of the study investigated the most suit-
able screening concentrations of FOX, ceftriaxone (CRO)
and ceftazidime (CAZ) for the detection of AmpC b-lacta-
mases in Klebsiella spp., E. coli, P. mirabilis and Salmonella spp.,
using control organisms and recent clinical isolates with
known AmpC b-lactamases (Table 2). The third part of the
study investigated the prevalence of these enzymes among
recent clinical isolates of Klebsiella spp., E. coli, P. mirabilis and
Salmonella spp. from the Calgary Health Region over a 1-year
period from April 2006 to March 2007 using the best
screening agent (as determined in Part 2) and conﬁrming the
result with the boronic acid-based disk test (as determined
in Part 1).
TABLE 2. Screening concentrations for control and recent
clinical isolates (n = 72) of AmpC-producing Escherichia coli,








£ 8 1 (1%) 1 (1%)
16 0 0
32 26 (36%) 31 (43%)
> 32 45 (63%) 40 (56%)
Total 72 72
CAZ
£ 2 25 (35%) 25 (35%)
4 6 (8%) 8 (11%)
8 8 (11%) 10 (14%)
16 14 (19%) 16 (22%)
> 16 19 (26%) 13 (18%)
Total 72 72
CRO
£ 2 22 (31%) 22 (31%)
4 8 (11%) 11 (15%)
8 10 (14%) 13 (18%)
16 13 (18%) 15 (21%)
> 16 19 (26%) 11 (15%)
Total 72 72
aAmpC-producing isolates consisted of seven control strains (MOX-1, FOX-1,
MIR-1, ACT-1, DHA-1, CMY-2, ACC-1) and the following recent clinical iso-
lates: E. coli with CMY-2 (n = 40), Salmonella spp. with CMY-2 (n = 10), K. pneu-
moniae with CMY-like, FOX-like and DHA-like enzymes (n = 10) and P. mirabilis
with CMY-like enzymes (n = 5). Refer to Table 1.
FOX, cefoxitin; CRO, ceftriaxone; CAZ, ceftazidime.
TABLE 1. Veriﬁcation and validation of the AmpC disk test
with control and recent clinical strains of Klebsiella spp.,













E. coli A2 MOX-1 Negative Positive
E. coli A3 FOX-1 Negative Positive
E. coli A4 MIR-1 Positive Positive
K. pneumoniae A5 ACT-1 Negative Positive
K. pneumoniae A8 DHA-1 Positive Positive
Salmonella spp. A6 CMY-2 Positive Positive
K. pneumoniae A7 ACC-1 Negative Negative
K. pneumoniae C2 KPC-2 Positive Positive
E. coli CTX2 CTX-M-15 Negative Negative
E. coli SHV-2 Negative Negative
E. coli T1 TEM-3 Negative Negative
Recent clinical isolates
aE. coli (n = 40) CMY-like Positive (36/40) Positive (40/40)
bSalmonella spp.
(n = 10)






Positive (7/10) Positive (10/10)
cP. mirabilis (n = 5) CMY-like Positive (4/5) Positive (5/5)






aReference [5] and 35 E. coli isolated in 2004, 2005 at Calgary Laboratory Ser-
vices (CLS) that tested AmpC negative with cefoxitin agar medium (CAM)
method [12] and multiplex PCR [10] bReference [9].
cRecent isolates from CLS as identiﬁed with multiplex PCR [10].
FOX, cefoxitin; CTT, cefotetan; PBA, phenylboronic acid.
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Phenylboronic acid disk conﬁrmation test
The disks were prepared as follows: 120 mg of PBA (also
known as benzeneboronic acid/anhydride) (Alfa Aesar, Ward
Hill, MA, USA) was dissolved in 3 mL dimethyl sulphoxide
(Alfa Aesar). Three millilitres of sterile distilled water was
added to this solution to create a stock solution; 20 lL of
the stock solution was dispensed onto each of 30 lg CTT,
30 lg FOX and blank disks (6 mm in diameter). These disks
had been obtained from Oxoid Inc. (Nepean, ON, Canada).
The disks were allowed to dry for 30 min and used either
immediately or stored in airtight vials with desiccant at 4 C.
An increase of ‡ 5 mm in zone diameter in the presence of
PBA compared with either CTT or FOX tested alone was
considered to represent a positive test for the presence of
an AmpC b-lactamase [7,8].
Veriﬁcation of the test
The accuracy of the AmpC disk test was determined using
11 strains with well-described resistance mechanisms
(Table 1); reproducibility was investigated by performing the
assay in triplicate on consecutive days. Recent clinical
AmpC-producing E. coli and Salmonella isolates described in
previous studies were also included to test the performance
of the assay [5,9]. These included 50 isolates with CMY
types of b-lactamases and 50 that were resistant to FOX
but tested AmpC negative (Table 1). We also selected 10
K. pneumoniae with CMY-like (n = 2), FOX-like (n = 7),
DHA-like (n = 1), and ﬁve P. mirabilis with CMY-like
enzymes. These bacteria were previously isolated at Calgary
Laboratory Services (CLS) during 2000–2005 and the cepha-
losporinases were characterized with a multiplex PCR as
previously described [10].
Screening for AmpC-producing bacteria
To determine the most appropriate screening concentrations
of FOX, CAZ and CRO that would detect AmpC-producing
Klebsiella spp., E. coli, P. mirabilis and Salmonella spp., the fol-
lowing isolates were included in Part 2 of the study: seven
control strains (with MOX-1, FOX-1, MIR-1, ACT-1, DHA-
1, CMY-2, ACC-1) and 65 recent clinical isolates (E. coli with
CMY-like (n = 40), Salmonella spp. with CMY-2 (n = 10),
K. pneumoniae with CMY-like, FOX-like and DHA-like
enzymes (n = 10) and P. mirabilis with CMY-like enzymes
(n = 5)). These bacteria were the same as those used in
Part 1 of the study (Tables 1 and 2). The minimum inhibitory
concentrations (MICs) were determined with Microscan
gram-negative (NMIC30; Dade Behring Canada Inc., Mississa-
uga, ON, Canada) and conﬁrmed with Vitek 2 using AST-
N019 panels (Vitek AMS; bioMe´rieux Vitek Systems Inc.,
Hazelwood, MO, USA). The quality control strain used for
this part of the study was E. coli ATCC 25922.
Bacterial isolates
Consecutive non-duplicate isolates of Klebsiella spp., E. coli,
P. mirabilis and Salmonella spp. (one per patient) collected at
CLS during April 2006 to March 2007 were included in Part
3 of this study (Table 3). Strains were identiﬁed to species
level with Vitek 2 (Vitek AMS; bioMe´rieux Vitek Systems
Inc.). MICs of the following drugs were determined with
Vitek 2 using AST-N019 panels (Vitek AMS; bioMe´rieux
Vitek Systems Inc.): ceftriaxone (CRO); ceftazidime (CAZ);
cefepime (FEP); cefoxitin (FOX); imipenem (IPM); gentamicin
(GEN); tobramycin (TOB); trimethoprim-sulphamethoxazole
(SXT); nitrofurantoin (NIT), and ciproﬂoxacin (CIP).
Throughout this study, results were interpreted using CLSI
TABLE 3. Prevalence and susceptibility of AmpC b-lactamases among clinical bacterial isolates of Escherichia coli, Klebsiella






Non-susceptibility to: n (%)
SXT GEN TOB NIT CIP FEP IPM
E. coli 25 109 560 310 77 51 35 10 56 0 0
(25%) (16%) (11%) (3%) (18%)
K. pneumoniae 2818 47 12 3 1 1 1 2 0 0
(25%) (8%) (8%) (8%) (17%)
K. oxytoca 505 12 0 0 0 0 0 0 0 0
P. mirabilis 1197 6 2 1 0 0 1 1 0 0
(50%) (50%) (50%)
Salmonella spp. 211 10 8 2 1 1 1 1 0 0
(25%) (13%) (13%) (13%) (13%)
Total 29 840 635 332 83 53 37 13 60 0 0
(25%) (16%) (11%) (4%) (18%)
a Using cefoxitin (FOX) at ‡ 32 mg/L with Vitek 2.
bUsing cefotetan and phenylboronic acid (PBA) (see Materials and methods for details.
Additional susceptibility testing in this study using the CLSI disk method shows resistance of 31% (103/332) to sulphisoazole, 23% (76/332) to chloramphenicol, 34% (114/
332) to tetracycline and 20% (65/332) to streptomycin .
SXT, trimethoprim-sulphamethoxazole; GEN, gentamicin; TOB, tobramycin; NIT, nitrofurantoin; CIP, ciproﬂoxacin; FEP, cefepime; IPM, imipenem.
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criteria for broth dilution [11]. The quality control strains
used for this part of the study were E. coli ATCC 25922 and
E. coli ATCC 35218.
Results
Part 1: veriﬁcation of the PBA disk test
The one-off process of determining the accuracy of the test
was performed using the 11 strains with well-described resis-
tance mechanisms and the recent clinical isolates (Table 1).
Most of the control strains were accurately detected by
CTT with PBA. However, A-7 (ACC-1) tested negative and
C2 (KPC-2) tested positive.
FOX with PBA did not detect the following control
strains: A2 (MOX-1); A3 (FOX-1); A5 (ACT-1), and A7
(AAC-1), whereas C2 (KPC-2) tested positive (Table 1). The
CTT with PBA test performed adequately with all the recent
clinical isolates with AmpC cephalosporinases (n = 65) that
tested positive, whereas those isolates resistant to cefoxitin
but AmpC-negative (n = 50) tested negative (Table 1). FOX
with PBA did not detect 10 of 65 recent clinical isolates with
AmpC cephalosporinases. Overall, the sensitivities of CTT
with PBA, and FOX with PBA, were 99% and 81%, respec-
tively, and the speciﬁcity of CTT with PBA, and FOX with
PBA, was 98% in both cases.
The performance of the inhibitor test was compared with
another recently described AmpC detection method called
the cefoxitin agar medium (CAM) test and showed identical
results with positive and negative control organisms [12].
Reproducibility (determined by performing the assay in tripli-
cate on consecutive days with the 11 control strains)
showed the same results with CTT and FOX on each occa-
sion. On this basis, CTT and PBA were used for the conﬁr-
mation of AmpC b-lactamases during Part 3 of the study.
Part 2: screening agents for AmpC-producing bacteria
MICs determinations using Microscan panels with FOX, CAZ
and CRO showed the following: a total of 71/72 (99%) had
MICs ‡ 32 mg/L of FOX; 47/72 (65%) had MICs > 2 mg/L of
CAZ, and 50/72 (69%) had MICs > 2 mg/L of CRO (Table 2).
MICs determined with Vitek 2 showed similar results (there
was a one-dilution difference with FOX in ﬁve isolates, with
CAZ in six and with CRO in eight) (Table 2). It was interest-
ing to note that none of the control strains or recent clinical
isolates had an MIC of 16 mg/L of FOX (the one isolate with
an MIC £ 8 mg/L was K. pneumoniae A7, producing ACC-1).
We performed AmpC testing (using the PBA conﬁrmation
disk test) on 101 clinical isolates of E. coli, Klebsiella spp.
Salmonella spp. and P. mirabilis (isolated at CLS during
2000–2005) with a FOX MIC of 16 mg/L and none tested
positive. Therefore, we decided to use FOX at ‡ 32 mg/L as
an adequate concentration to screen for AmpC producing E.
coli, Klebsiella spp., Salmonella spp. and P. mirabilis.
Part 3: prevalence among the clinical bacterial isolates
A total of 29 840 non-repeat bacteria (i.e. one isolate per
patient) were isolated at CLS over a 12-month period from
April 2006 to March 2007 and were included in Part 3 of
the study (Table 3). These consisted of 25 109 (84%) E. coli,
2818 (9%) K. pneumoniae, 505 (2%) Klebsiella oxytoca, 1197
(4%) P. mirabilis, and 211 (1%) Salmonella species. Of these,
635 (2%) were found to be resistant to cefoxitin (MIC
‡ 32 ug/mL) and 332/635 (52%) were positive for AmpC
cephalosporinases using the conﬁrmation disk test with CTT
and PBA. The majority were E. coli (310/332, 93%), followed
by K. pneumoniae (12/332, 4%), Salmonella spp. (8/332, 2%),
and P. mirabilis (2/332, 1%). The majority of isolates (206/332,
62%) were submitted from community collection sites. Of
the 332 AmpC b-lactamase-producing isolates, 83 (25%)
were non-susceptible to SXT, 37 (11%) to TOB, 53 (16%) to
GEN, 13 (4%) to NIT and 60 (18%) to CIP. No resistance
was detected to IPM or FEP.
Discussion
Organisms with plasmid-mediated AmpC enzymes are mostly
responsible for nosocomial outbreaks on a worldwide basis. A
study reported by Pai et al., showed that patients infected with
plasmid-mediated AmpC-producing K. pneumoniae had similar
clinical features and outcomes as patients infected with TEM-
or SHV-related extended-spectrum b-lactamase producers
[13]. Furthermore, if combined with decreased outer mem-
brane permeability, bacteria with such enzymes can become
resistant to carbapenems [14]. Therefore, it is important to
detect AmpC-producing organisms to ensure effective thera-
peutic intervention and optimal clinical outcome, as well as to
control the spread of these organisms. However, most current
methods for detection of these enzymes are technically
demanding and time-consuming and therefore unsuitable for
clinical laboratories to perform on a routine basis [6].
This study showed that an inhibitor-based PBA disk conﬁr-
mation test with cefotetan is a simple and reliable conﬁrmation
method for use in clinical laboratories. This assay uses meth-
odology similar to that of the CLSI Xxx [extended-spectrum
b-lactamase (ESBL)] phenotypic conﬁrmatory disk test. This
test was easy to perform, interpret and incorporate into the
workﬂow of our high-volume laboratory. Although CTT with
PBA gave the best performance overall for detection of AmpC
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enzymes, it was unable to detect ACC-1 (Table 1). ACC-1
originated from the chromosomal cephalosporinase of H. alvei
and is different from most other plasmid-mediated AmpC
b-lactamases in that isolates with this enzyme are sensitive to
the cephamycins (i.e. cefoxitin), but show decreased suscepti-
bility to ceftazidime [15]. Bacteria with ACC-1 are relatively
rare and have only been reported from countries such as the
UK [16], Germany [17] and France [18]. Isolates (i.e. E. coli,
Klebsiella spp. and P. mirabilis) that are intermediate to ceftazi-
dime and sensitive to cefoxitin, combined with a negative ESBL
conﬁrmatory test, can be further tested with the cefoxitin
double-disk test to conﬁrm the presence of ACC-1 [15].
Phenylboronic acid inhibited K. pneumoniae C2 producing
KPC-2 and gave a false-positive AmpC disk test result
(Table 1). A false-positive reaction has also been previously
described with different AmpC inhibitors in KPC-producing
strains [19,20]. KPC-producing bacteria are causing a pan-
demic and have been shown to be widespread in enterobac-
terial species including Klebsiella spp. and E. coli from certain
areas of the USA and Europe [21]. Clinical laboratories need
to be aware of the fact that KPC causes resistance to the
cephamycins and can test positive with inhibitor-based AmpC
disk conﬁrmation tests. Klebsiella spp., E. coli, Salmonella spp.
and P. mirabilis that test positive for AmpC cephalosporinases
with subsequent decreased susceptibility to the carbapenems
(e.g. ertapenem) should be referred to a reference labora-
tory to investigate for possible KPC production [22].
In summary, clinical laboratories should routinely screen
for AmpC cephalosporinases in Klebsiella spp., E. coli, Salmo-
nella spp. and P. mirabilis with a cefoxitin MIC ‡ 32 mg/L and
conﬁrm the presence of these enzymes using the PBA disk
conﬁrmation test with cefotetan described herein. This
approach is convenient, practical and easy to incorporate into
the workﬂow of a clinical laboratory. Laboratories should also
be aware that KPC-producing bacteria can test false-positive
for AmpC b-lactamases with inhibitor-based methods.
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